tbuckley/cabot-search huggingface dataset:
Cost-Effectiveness Analysis of Lung Cancer Screening in the United States
Authors: Steven D. Criss, Pianpian Cao, Mehrad Bastani, Kevin ten Haaf, Yufan Chen, Deirdre F. Sheehan, Erik F. Blom, Iakovos Toumazis, Jihyoun Jeon, Harry J. de Koning, Sylvia K. Plevritis, Rafael Meza, Chung Yin Kong
Journal: Annals of Internal Medicine (2019)

Background: Recommendations vary regarding the maximum age at which to stop lung cancer screening: 80 years according to the U.S. Preventive Services Task Force (USPSTF), 77 years according to the Centers for Medicare & Medicaid Services (CMS), and 74 years according to the National Lung Screening Trial (NLST). Objective: To compare the cost-effectiveness of different stopping ages for lung cancer screening. Design: By using shared inputs for smoking behavior, costs, and quality of life, 4 independently developed microsimulation models evaluated the health and cost outcomes of annual lung cancer screening with low-dose computed tomography (LDCT). Data Sources: The NLST; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial; SEER (Surveillance, Epidemiology, and End Results) program; Nurses' Health Study and Health Professionals Follow-up Study; and U.S. Smoking History Generator. Target Population: Current, former, and never-smokers aged 45 years from the 1960 U.S. birth cohort. Time Horizon: 45 years. Perspective: Health care sector. Intervention: Annual LDCT according to NLST, CMS, and USPSTF criteria. Outcome Measures: Incremental cost-effectiveness ratios (ICERs) with a willingness-to-pay threshold of $100 000 per quality-adjusted life-year (QALY). Results of Base-Case Analysis: The 4 models showed that the NLST, CMS, and USPSTF screening strategies were cost-effective, with ICERs averaging $49 200, $68 600, and $96 700 per QALY, respectively. Increasing the age at which to stop screening resulted in a greater reduction in mortality but also led to higher costs and overdiagnosis rates. Results of Sensitivity Analysis: Probabilistic sensitivity analysis showed that the NLST and CMS strategies had higher probabilities of being cost-effective (98% and 77%, respectively) than the USPSTF strategy (52%). Limitation: Scenarios assumed 100% screening adherence, and models extrapolated beyond clinical trial data. Conclusion: All 3 sets of lung cancer screening criteria represent cost-effective programs. Despite underlying uncertainty, the NLST and CMS screening strategies have high probabilities of being cost-effective. Primary Funding Source: CISNET (Cancer Intervention and Surveillance Modeling Network) Lung Group, National Cancer Institute.
CRISPR Screens Identify Mechanisms of Natural Killer Cell Evasion across Blood Cancers
Authors: Olli Dufva, Khalid Saeed, Sara Gandolfi, Michal Sheffer, Jay Klievink, Petri Pölönen, Tiina Hannunen, Mette Ilander, Pekka Ellonen, Matti Kankainen, Dean Anthony Lee, Constantine S. Mitsiades, Satu Mustjoki
Journal: Blood (2019)
XPO1 Mutations May Identify Binet Α Chronic Lymphocytic Leukemia Patients with Shorter Time to First Treatment
Authors: Riccardo Moia, Chiara Favini, Sruthi Sagiraju, Valeria Spina, Alessio Bruscaggin, Silvia Rasi, Lorenzo De Paoli, Clara Deambrogi, Mattia Schipani, Ahad Ahmed Kodipad, Davide Rossi, Gianluca Gaidano
Journal: Blood (2019)
TMIC-10. THE ROLE OF THE BRAIN MICROENVIRONMENT IN THE MIGRATION OF BREAST CANCER CELLS IN BRAIN METASTASES
Authors: Cymon Kersch, Leslie Muldoon, DreeAnna Morris, Edward Neuwelt
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Breast cancer brain metastases have poor prognosis and few treatment options. When breast cancer cells invade the brain they interact with the vasculature and resident brain cells including microglia and astrocytes. We hypothesize that brain cells produce factors that enhance the growth and invasion of breast cancer cells in the brain. METHODS Human breast cancer cell lines (MDA-MB231BR-HER2 and HCC1954) were inoculated intracranially in athymic rats as xenograft models of brain metastasis. Brains were analyzed for pro-tumorigenic factor expression in the tumor microenvironment using fluorescent immunohistochemistry. In vitro assays assessed factors involved in breast cancer cell proliferation, morphology, and migration. RESULTS The tumor xenografts showed infiltration intothe perivascular space. Galectin-3 (Gal3), heparin-binding epidermal growth factor (HB-EGF), and Neuregulin (NRG1), factors known to interact with receptors expressed by breast cancer cells, co-localized with reactive microglia (Gal3) and astrocytes (HB-EGF and NRG1) in and around xenografts. In vitro, these factors individually increased HCC1954 cell proliferation and/or migration. In transwell co-culture assays, BV2 microglial cells increased the migration of HCC1954 cells &gt;25 fold, which was prevented by cilengitide, an inhibitor of αvβ3-integrin cell adhesion protein. ELISA analysis demonstrated that BV2 microglia secrete Gal3 in the presence of HCC1954 cells. Gal3 is known to bind and induce clustering of αvβ3-integrin which is expressed on metastatic breast cancer cells. Immunohistochemistry of clinical specimens revealed that Gal3 is expressed in/around human breast cancer brain metastases. CONCLUSIONS These data suggest that factors produced in the tumor microenvironment promote the growth and migration of breast cancer cells in the brain. Gal3, produced and secreted by activated microglia in vitro and expressed in and around brain metastases, increases the invasive capability of breast cancer cells. The interactions of neoplastic cells with the brain environment may provide a target to improve therapy of brain metastases.
Surgical Aspects of Roundworm Disease
Authors: J. F. E. Gillam
Journal: BMJ (1947)

JBUTISH from disintegration and families enabled once again to take their place as self-directing and self-respecting members of the community.Co-ordination of existing work and the co- operation of all agencies concerned with the problem are essential.The aim of F.S.U. is to provide a service at the disposal of other departments and bodies to be used by them on particular cases needing specialized treatment.The committee plan first to take responsibility for the exist- ing work in Liverpool and Manchester, and then to establish a new unit in London as soon as personnel becomes available.The keynote of successful work in this field must be friend- ship, and the work will call for personal self-sacrifice of a high order.The work of the committee will continue for some time to be experimental.The problem family tails to utilize or benefit from such faci ities for its betterWnt as exist at present.Rehousing, family -allowances, and a national medical service are not enough.This is a task in which voluntary effort and personal service in the home must play a preponderant part, and it is a task in which personal service alone can be successful.Among the objects we have in view is a comprehensive investi- gation into the nature, extent, and causes of this form of social subnormality.A two years' period will, we think, be sufficient to establish the facts, and we ask for a sum of £15,000, which is sufficient to support the existing centres during that time and to establish one new centre in London.
Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease
Authors: Veronica Alfieri, Ernesto Crisafulli, Dina Visca, Wing Ho Chong, Carmel Stock, Letizia Mori, Angelo de Lauretis, Vicky Tsipouri, Felix Chua, Vasilis Kouranos, Maria Kokosi, Charlotte Hogben, Philip L. Molyneaux, Peter M. George, Toby M. Maher, Alfredo A. Chetta, Piersante Sestini, Athol U. Wells, Elisabetta A Renzoni
Journal: European Respiratory Journal (2019)

<b>In patients with interstitial lung disease, exertional hypoxaemia has quality of life and prognostic implications. A simple "DeOX" score predictive of exertional oxygen desaturation (<i>S</i><sub>pO<sub>2</sub></sub></b><b>≤88% on 6MWT) is proposed, using <i>S</i><sub>pO<sub>2</sub></sub></b><b>at rest and <i>D</i><sub>LCO</sub>.</b>http://bit.ly/36ytigE
Quantification of Humoral Immune Response to Influenza Vaccination in MDS
Authors: Pankit Vachhani, Kyle Wiatrowski, Pragya Srivastava, Lisa King, Jody Manischewitz, Hana Golding, Heather L Bashaw, Ava R. Dimitroff, Amanda Przespolewski, James E. Thompson, Swapna Thota, Eunice S. Wang, Michael J. Nemeth, Elizabeth A. Griffiths
Journal: Blood (2019)
CRISPR/Cas9-Mediated Protection of Normal Hematopoiesis Combined with the CD33/CD3 Bispecific T-Cell Engager (BiTE) Antibody AMG330 for Improved AML Therapy
Authors: Olivier Humbert, Mallory J Llewellyn, George S. Laszlo, Roland B. Walter, Hans-Peter Kiem
Journal: Blood (2019)
Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience
Authors: Elena Maria Elli, Ambra Di Veroli, Alessandra Iurlo, Ida Carmosino, Giulia Benevolo, Elisabetta Abruzzese, Massimiliano Bonifacio, Emanuele Sutto, Nicola Polverelli, Marianna Caramella, Daniela Cilloni, Mario Tiribelli, Giovanni Caocci, Elena Crisà, Raffaele Porrini, Rossella Renso, Uros Markovic, Daniele Cattaneo, Lucia Biale, Michela Ansuinelli, Malgorzata Monika Trawinska, Luigi Scaffidi, Massimo Breccia, Carlo Gambacorti-Passerini, Giuseppe A. Palumbo, Roberto Latagliata
Journal: Blood (2019)
Eltrombopag (ELT) Reverses Iron Mediated Suppression of Insulin Secretion in Pancreatic Cells By Chelating Iron and Decreasing ROS
Authors: Evangelia Vlachodimitropoulou Koumoutsea, Pimpisid Koonyosying, John B. Porter, Nichola Cooper, Bethan Psaila, Martha Sola-Visner
Journal: Blood (2016)
Novel Insights Regarding Pediatric Essential Thrombocythemia
Authors: Assaf Arie Barg, Gili Kenet, Tami Livnat, Gal Goldstein, Joanne Yacobovich, Oded Gilad, Orna Steinberg Shemer, Shoshana Revel-Vilk, Hagit Miskin, Amos Toren, Vered Shkalim
Journal: Blood (2019)
ANGI-13. PLEXIN-B2 FACILITATES DIFFUSE GLIOMA INVASION BY REGULATING CELL ADHESION AND ACTO-MYOSIN DYNAMICS
Authors: Yong Huang, Rut Tejero, Vivian Lee, Chrystian Junqueira Alves, Ramsey Foty, Guohao Dai, Hongyan Zou, Roland Friedel
Journal: Neuro-Oncology (2019)

Abstract Diffuse invasion of glioblastoma (GBM) cells into brain tissue is a key factor for its high lethality. GBM cell migration is affected by functions of plexins, which are transmembrane receptors of semaphorins that regulate cell adhesion and cytoskeletal dynamics. Expression of Plexin-B2 is upregulated in GBM and correlates with malignancy. We show here that Plexin-B2 activity regulates biomechanical properties of GBM cells, promoting invasive growth. Plexin-B2 activity increased the capacity of GBM to invade as dispersed single cells by reducing the cell-cell adhesiveness between GBM cells, indicating that a major function of Plexin-B2 activity is to downregulate cell-cell adhesion systems. RNA-Seq analyses also revealed that GBM stem cells (GSC) with deletion of Plexin-B2 altered expression of genes related to cell adhesion and the matrisome, indicating compensatory mechanisms in cellular dynamics. Interestingly, in vivo intracranial transplant studies demonstrated that growth and invasion of Plexin-B2 mutant GSC was impaired, with mutant cells invading shorter distances and migrating mainly as groups of cells forming chains. Plexin-B2 mutant cells also were more likely to adhere to the vasculature, rather than to fiber tracts, suggesting altered biomechanical properties. This shift may be related to high stiffness of basal lamina of the vasculature, as Plexin-B2 KO cells have a preference for migration on stiff substrate in vitro. Intriguingly, the loss in Plexin-B2 expression also changed the distribution of the mechanosensor transction factor YAP, with high expression of Plexin-B2 correlating with increased nuclear YAP. Structure-function analyses revealed that the Ras-GAP domain as main signaling output of Plexin-B2. The Rap proteins are pleiotropic regulators of cell adhesion and actomysosin contractility. Our data also showed that overexpression of Plexin-B2 can lead to decreased levels of Rap1/Rap2. Thus, Plexin-B2 acts as a key regulator of the adhesion and contractility of GBM cells, thereby facilitating their diffuse invasion.
Recurrent Venous and Arterial Thrombosis By Prothrombin p.R596Q Heterozygous Mutation in a Chinese Patient: A Case Report and Literature Review
Authors: Rong-Fu Zhou, WANG JUN, Xu Peng, Hui Zeng, Yong Xu, Yueyi Xu, Min Zhou, Peipei Xu, Bing Chen
Journal: Blood (2019)
EPID-28. WHAT DO PATTERNS OF “UNCLASSIFIED” BRAIN TUMORS TELL US ABOUT INCIDENCE RATES OF NON-MALIGNANT BRAIN TUMORS IN CANADA?
Authors: Trenton Smith, Emily Walker, Yan Yuan, Faith Davis, Joseph Megyesi
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Patients with non-malignant brain tumors (NMBT) can experience significant morbidity and mortality; the degree of which varies by histological subtype. A recent report on all primary brain tumors in Alberta (AB), British Columbia (BC), Manitoba (MB) and Ontario (ON) showed 19.1% of NMBT were categorized as ‘unclassified’. Missing data on histological subtypes encumbers efforts to understand the burden of disease associated with NMBT. The purpose of this analysis was to examine the distribution of unclassified tumors across participating provinces to identify targets for improved surveillance. METHODS Data were provided from cancer registries in AB, BC,MB, and ON. Age Standardized Incidence Rates (ASIR) and frequencies were estimated using SAS 9.4. Given data from the United States (U.S) is accurate and the population is comparable, ASIR of NMBT in the U.S were used as expected values in this analysis. The 2011 Canadian Population and the 2000 US population were used for standardization to compare within Canada and to U.S data respectively. RESULTS The ASIR of total NMBT and was highest in ON, relative to other participating provinces and similar to that of the U.S (15.25 and 15.91 cases/100,000 person-years, respectively). However, ON had an ASIR about 10 times higher than other provinces for unclassified tumors (ON:6.3 cases/100,000 person-years; BC: 0.4 cases/100,000 person-years; AB:0.3 cases/100,000 person-years; and MB:0.6 cases/100,000 person-years). When unclassified tumors were excluded from the analysis, the ASIR of NMBT was similar across participating provinces. CONCLUSIONS Findings from this analysis indicate that the Ontario provincial cancer registry has complete data on total NMBT cases. However, the high ASIR of unclassified cases in the NMBT category indicates that quality control measures could be improved. Further examination of the unclassified cases in ON could be used to improve the accuracy of the ON cancer registry and the completeness of other province’s registries.
Distinct Subgroups in Hypertrophic Cardiomyopathy in the NHLBI HCM Registry
Authors: Stefan Neubauer, Paul Kolm, Carolyn Y. Ho, Raymond Y. Kwong, Milind Y. Desai, Sarahfaye F. Dolman, Evan Appelbaum, Patrice Desvigne-Nickens, John P. DiMarco, Matthias G. Friedrich, Nancy Geller, Andrew R. Harper, Petr Jarolim, Michael Jerosch-Herold, Dong-Yun Kim, Martin S. Maron, Jeanette Schulz-Menger, Stefan K. Piechnik, Kate Thomson, Cheng Zhang, Hugh Watkins, William S. Weintraub, Christopher M. Kramer, Masliza Mahmod, Daniel Jacoby, James White, Amedeo Chiribiri, Adam Helms, Lubna Choudhury, Michelle Michels, William Bradlow, Michael Salerno, Stephen Heitner, Sanjay Prasad, Saidi Mohiddin, Peter Swoboda, Heiko Mahrholdt, Chiara Bucciarelli-Ducci, Jonathan Weinsaft, Han Kim, Gerry McCann, Albert van Rossum, Eric Williamson, Andrew Flett, Dana Dawson, F. Pierre Mongeon, Iacopo Olivotto, Andrew Crean, Anjali Owens, Lisa Anderson, Elena Biagini, David Newby, Colin Berry, Bette Kim, Eric Larose, Theodore Abraham, Mark Sherrid, Sherif Nagueh, Ornella Rimoldi, Eleanor Elstein, Camillo Autore
Journal: Journal of the American College of Cardiology (2019)
Electroactive composite scaffold with locally expressed osteoinductive factor for synergistic bone repair upon electrical stimulation
Authors: Liguo Cui, Jin Zhang, Jun Zou, Xianrui Yang, Hui Guo, Huayu Tian, Peibiao Zhang, Yu Wang, Ning Zhang, Xiuli Zhuang, Zhongming Li, Jianxun Ding, Xuesi Chen
Journal: Biomaterials (2019)
Intrauterine contraceptive devices.
Authors: M. R. Neely
Journal: BMJ (1966)

penal system, but since the major part of the problem is a social one, so also the " cure " must be viewed in social rather than medical terms.I agree entirely with Dr. Scott that voluntary effort has not failed, it has simply not been tried.Society is reluctant to accept its own responsibility in this matter and is only too ready to hand this over to the " experts," whether these be medical or criminological.The community needs help to look after its own misfits and rejects, and I am only sorry that the subcommittee did not pay more attention to this aspect of the problem, however necessary the setting up of special institutions might be in addition .-I.am,etc.,
CMET-40. IMPACT OF WHOLE BRAIN RADIOTHERAPY ON LEPTOMENINGEAL METASTASIS FROM NON-SMALL CELL LUNG CANCER
Authors: Lei Wen, Zhaoming Zhou, Junjie Zhen, Cheng Zhou, Mingyao Lai, Changguo Shan, Linbo Cai
Journal: Neuro-Oncology (2019)

Abstract BACKGROUND Leptomeningeal metastasis (LM) is a detrimental complication of patients with non-small cell lung cancer (NSCLC) and its incidence has increased due to recent improvements in survival. The aim of this study was to assess the impact of whole brain radiotherapy (WBRT), chemotherapy and epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) on survival. METHODS Seventy-four consecutive patients diagnosed with LM from NSCLC between 2009 and 2018 in Sanjiu Brain Hospital were retrospectively reviewed. Survival was assessed by Kaplan-Meier analyses. RESULTS The median age was 54.5 (range 30–76) years. LM were diagnosed by MRI (36/74), cytology (4/74), or both (34/74). Eighteen patients (24.3%) were diagnosed at the initial presentation of lung cancer. Forty-seven (63.5%) patients harboring EGFR positive mutation while other twenty-seven patients (36.5%) were EGFR wild type. The median overall survival from diagnosis of LM was 8.1 months (95% confidence interval: 5.2 to 11.0). Patients who received EGFR-TKIs after LM had longer survival than those who did not (10.5 vs. 4.4 months, p＜0.001). No significant differences in survival were seen between patients who were treated with WBRT and those without, whether in EGFR mutation positive patients (11.6 vs. 15.0 months, p=0.353), or in EGFR wild type ones (5.1 vs. 3.3 months, p=0.116). Similarly, intravenous chemotherapy after LM had no impact on overall survival (7.5 vs. 8.1 months, p=0.9). CONCLUSION Median overall survival was higher than historical experience in our retrospective analysis. Survival was not improved by WBRT or intravenous chemotherapy. EGFR-TKIs could prolong survival of patients with LM from NSCLC.
Effect of Early Post Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogenic Stem Cell Transplantation
Authors: Nidhi Sharma, Bin Ni, Qiuhong Zhao, Patrick Elder, Don M. Benson, Ashley E. Rosko, Maria Chaudhry, Naresh Bumma, Abdullah Mohammad Khan, Srinivas Devarakonda, Sumithira Vasu, Samantha Jaglowski, Basem M. William, Alice S. Mims, Hannah K. Choe, Karilyn Larkin, Jonathan E Brammer, Sarah A Wall, Nicole Grieselhuber, Ayman Saad, Sam Penza, Yvonne A. Efebera
Journal: Blood (2019)
Clinical Outcomes and Healthcare Utilization in Patients with Sickle Cell Disease: A Nationwide Cohort Study of Medicaid Beneficiaries
Authors: Rishi J Desai, Mufaddal Mahesri, Raisa Levin, Denise Globe, Krista McKerracher, Alex Mutebi, Rhonda Bohn, Maureen Achebe, Sebastian Schneeweiss
Journal: Blood (2019)
Improved Overall Survival Among Newly Diagnosed Aggressive Adult T-Cell Leukemia/Lymphoma Patients Treated with Mogamulizumab Plus EPOCH Compared to Mogamulizumab Plus Vcap-AMP-Vecp
Authors: Tatsuro Jo, Kaori Matsuzaka, Haruna Shioya, Hiroo Tominaga, Takahiro Sakai, Yohei Kaneko, Shizuka Hayashi, Masatoshi Matsuo, Jun Taguchi, Kazuto Shigematsu
Journal: Blood (2019)
Thrombotic Risk Assessment in a Prospective Cohort of Newly Diagnosed Ambulatory Cancer Patients Candidate to Chemotherapy
Authors: Anna Falanga, Cristina Verzeroli, Marina Marchetti, Cinzia Giaccherini, Laura Russo, Giovanna Masci, Luigi Celio, Roberta Sarmiento, Sara Gamba, Carmen J Tartari, Erika Diani, Alfonso Vignoli, Paolo Malighetti, Daniele Spinelli, Carlo Tondini, Sandro Barni, Francesco Giuliani, Fausto Petrelli, Andrea D'Alessio, Giampietro Gasparini, Filippo De Braud, Armando Santoro, Roberto Labianca
Journal: Blood (2019)
Acute Non-specific Gastro-enteritis
Authors: B. P. Marmion, G. T. Cook
Journal: BMJ (1948)

in visual acuity would result.The easing or abolition of head- ache for as long as several days surprised us, as the effect of the drug on the blood pressure is short-lived, lasting from a few minutes to at most an hour or two.We therefore substi- tuted control injections of saline, elaborate and lengthy read- ings of blood pressure being taken as before, retinae and pupils being examined every few minutes.Equally satisfactory results in improvement in vision and lessening of headache were, reported by the patients after such "dummy" injections.Apart from this small group where improvement was effected by suggestion no really satisfactory results were obtained with the drug, and the high hopes we held for its being useful in treatment of hypertensive patients unsuitable for sympathec- tomy have not been fulfilled.We have found the effect of the drug on skin temperature of the extremities variable and erratic and less satisfactory than simpler methods.In some cases little or no drop in blood pressur rsulted, though most patients had some depression of systolic and diastolic pressure for 3 to 30 minutes after intravenous injection of 100-600 mg. of the drug.The rate of the injection appeared to play a part as well as the dosage given, the more rapid the administration of the drug the more the effect on the blood pressure.As stated in your annotation, T.E.A.B. is an impracticable therapeutic agent, but it may prove of use to the research worker.We have not found it a useful drug either in testing rises in peripheral skin temperature or in lessening symptoms in hypertensive subjects.In the last group of cases the psycho- genic element features largely in so many cases, and it is easy to produce symptomatic relief by suggestion backed by elabor- ate investigation.Nevertheless it is possible that new uses may yet be found for this drug, and our trial is still in progress.-I am, etc., London, S.W.I.F. DUDLEY HART.Acute Non-specific Gastro-enteritis SIR,-We note with interest the letter from Dr. William Forster (Dec. 13, 1947,p. 971) describing an outbreak of acute non-specific gastro-enteritis in a mental hospital, and we
Complications of Extra Fluid Therapy (Hyperhydration) in Sickle Cell Patients during Vaso-Occlusive Painful Crisis
Authors: Aafke E. Gaartman, Ajab K. Sayedi, Charlotte F.J. Van Tuijn, Harriet Heijboer, Tanja Netelenbos, Bart J. Biemond, Erfan Nur
Journal: Blood (2019)
Integrated Analysis of Copy-Number Alterations and Gene Mutations in 2,000 Patients with Myeloid Neoplasms
Authors: Ryunosuke Saiki, Yusuke Shiozawa, Tetsuichi Yoshizato, Yasuhito Nannya, June Takeda, Kenichi Yoshida, Yuichi Shiraishi, Hiroko Tanaka, Kenichi Chiba, Yoshiko Atsuta, Makoto Onizuka, Hidehiro Itonaga, Masashi Sanada, Yoshinobu Kanda, Bartlomiej Przychodzen, Mikkael A. Sekeres, Kathryn Guinta, Yogenthiran Saunthararajah, Lee-Yung Shih, Shuichi Miyawaki, Tsuyoshi Nakamaki, Masataka Taguchi, Shigeo Fuji, Nana Sasaki, Nobuhiko Uoshima, Yasunori Ueda, Yasushi Miyazaki, Kensuke Usuki, Kazunori Imada, Akifumi Takaori-Kondo, Shigeru Chiba, Senji Kasahara, Toru Kiguchi, Hisashi Tsurumi, Luca Malcovati, Mario Cazzola, Takayuki Ishikawa, Satoru Miyano, Jaroslaw P. Maciejewski, Hideki Makishima, Seishi Ogawa
Journal: Blood (2019)
Impact of HLA Class I Allele Mismatch on Viral Infection within 100 Days after Cord Blood Transplantation
Authors: Tomoki Iemura, Yasuyuki Arai, Junya Kanda, Toshio Kitawaki, Masakatsu Hishizawa, Tadakazu Kondo, Kouhei Yamashita, Akifumi Takaori-Kondo
Journal: Blood (2019)